A Retrospective Analysis of Patients with Short Stature in Eastern China between 2013 and 2019
Table 3
Clinical and biochemical characteristics of the rhGH-treated subjects.
Year
All
2013
2014
2015
2016
2017
2018
2019
Number
484
20
33
38
76
82
75
160
Sex (male %)
316 (65.29%)
14 (70.00%)
19 (57.58%)
28 (73.68%)
51 (67.11%)
58 (70.73%)
45 (60.00%)
101 (63.12%)
Age (years)
Bone age (years)
Height (cm)
Height SDS
BMI (kg/m2)
Peak GH (ng/ml)
6.78 (4.34-9.88)
6.73 (5.66-7.85)
4.34 (2.92-9.24)
7.44 (5.20-10.94)
6.70 (4.52-10.91)
6.64 (4.13-11.21)
7.11 (4.73-9.51)
6.38 (4.79-9.98)
IGF-1 (ng/ml)
196.00 (125.25-316.75)
173.87 (48.97-217.19)
171.50 (122.00-218.75)
158.00 (109.75-293.25)
180.00 (95.00-240.00)
201.50 (128.25-355.00)
216.50 (154.00-349.00)
206.00 (137.00-358.00)
IGF-1 SDS
-1.02 (-1.77--0.19)
-1.15 (-1.67--0.64)
-1.38 (-2.30--1.02)
-1.37 (-2.30--0.10)
-1.08 (-1.79--0.28)
-1.00 (-1.79--0.19)
-1.07 (-1.71--0.22)
-0.58 (-1.35-0.26)
Duration of rhGH treatment (years)
1.00 (1.00-2.00)
2.00 (1.00-3.50)
2.00 (1.00-3.00)
1.00 (1.00-2.00)
1.00 (1.00-2.00)
1.00 (1.00-2.00)
1.00 (1.00-2.00)
1.00 (1.00-1.00)
Pubertal stage
In prepuberty (%)
273 (56.40%)
11 (55.00%)
21 (63.64%)
25 (65.79%)
41 (53.95%)
47 (57.32%)
42 (56.00%)
86 (53.75%)
In puberty (%)
211 (43.60%)
9 (45.00%)
12 (36.36%)
13 (34.21%)
35 (46.05%)
35 (42.68%)
33 (44.00%)
74 (46.25%)
Abbreviations: height SDS: height standard deviation scores; IGF-1 SDS: insulin-like growth factor-1 standard deviation scores; peak GH: peak growth hormone; rhGH: recombinant human growth hormone; normal distribution of data was presented as ; nonnormal distribution of data was presented as median (interquartile range) and categorical data using number (percentage).
